Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?

被引：2
|
作者：
Blinman, Prunella Louise
Martin, Andrew James
Jefford, Michael
Goldstein, David
Boadle, David
Morris, Michelle Frances
Tebbutt, Niall C.
Aiken, Christine
Paul, James
Segelov, Eva
Haydon, Andrew Mark
Iveson, Tim
Stockler, Martin R.
机构：
[1] Concord Repatriat Gen Hosp, Concord, NSW, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[3] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Australia
[4] Prince Wales Hosp, Randwick, NSW, Australia
[5] Royal Hobart Hosp, Hobart, Tas, Australia
[6] Sunshine Coast Canc Serv, Nambour, Australia
[7] Heidelberg Repatriat Hosp, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Australia
[8] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[9] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[10] Monash Univ, Melbourne, Australia
[11] Monash Hlth, Melbourne, Australia
[12] Alfred Hosp, Melbourne, Australia
[13] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3602
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Adjuvant chemotherapy (ACT) for early colon cancer (ECC): What do investigators think makes it worthwhile?
    Beale, P
    Nowak, AK
    Duric, V
    Dhillon, H
    Stockler, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 547S - 547S
  • [12] Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC).
    Duric, V
    Stockler, MR
    Butow, P
    Sharpe, L
    Beith, J
    Sullivan, A
    Boyle, F
    Dhillon, H
    Coates, AS
    Simes, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 73S - 73S
  • [13] The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients' characteristics and safety analysis.
    Souglakos, John
    Boukovinas, Ioannis
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Androulakis, Nikolaos E. M.
    Ardavanis, Alexandros
    Kentepozidis, Nikolaos K.
    Vaslamatzis, Michael
    Athanasiadis, Athanasios
    Christopoulou, Athina
    Makrantonakis, Paris
    Polyzos, Aristidis
    Mavroudis, Dimitrios
    Mala, Anastasia
    Kalisperi, Aggeliki
    Xynogalos, Spyros
    Varthalitis, Ioannis I.
    Kouroussis, Charalambos
    Prinarakis, Efthimios
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [14] Patients' preferences for adjuvant chemotherapy for breast cancer: What makes it worthwhile in a Latin American population?
    Debiasi, M.
    Bozzetti, M. C.
    Barrios, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [15] PATIENTS' PREFERENCES FOR ADJUVANT CHEMOTHERAPY (ACT) IN EARLY NON-SMALL CELL LUNG CANCER (NSCLC): WHAT MAKES IT WORTHWHILE?
    Mclachlan, Sue-Anne
    Hughes, Brett
    Crombie, Catherine
    Christmas, Tim
    Hudson, Malcolm
    Brown, Chris
    Veillard, Anne-Sophie
    Muljadi, Nick
    Millward, Michael
    Wright, Gavin
    Flynn, Peter
    Windsor, Morgan
    Stockler, Martin
    Blinman, Prunella
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S625 - S626
  • [16] The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
    Trensz, P.
    Calvel, L.
    Kurtz, J. E.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1601 - 1601
  • [17] The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients' characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.
    Andre, Thierry
    De Gramont, Aimery
    Mineur, Laurent
    Desrame, Jerome
    Faroux, Roger
    Bennouna, Jaafar
    Dauba, Jerome
    Louvet, Christophe
    Pernot, Simon
    Dupuis, Olivier Jean Marie
    Becouarn, Yves
    Mabro, May
    Egreteau, Joelle
    Bouche, Olivier
    Bonnetain, Franck
    de larauze, Marine Hug
    Le Malicot, Karine
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [18] MAKING SENSE OF PATIENTS' PREFERENCES FOR ADJUVANT CHEMOTHERAPY (ACT) IN EARLY BREAST CANCER (EBC): WHAT MAKES IT WORTHWHILE, WHO DECIDES AND WHY?
    Duric, Vlatka
    Stockler, Martin
    Butow, Phyllis
    Sharpe, Louise
    QUALITY OF LIFE RESEARCH, 2004, 13 (09) : 1517 - 1517
  • [19] Adjuvant chemotherapy for patients with stage III colon cancer, three months vs six months. A single centre experience
    Martin-Montalvo, G.
    Martinez Perez, D.
    Ruiz-Gutierrez, I.
    Alameda, M.
    Rueda-Lara, A.
    Pena, J.
    Jimenez-Bou, D.
    Vinal, D.
    Garcia-Cuesta, J.
    Pedregosa Barbas, J.
    Rodriguez-Salas, N.
    Feliu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S114 - S114
  • [20] Clinicians' preferences for adjuvant chemotherapy (ACT) in non-small-cell lung cancer (NSCLC): what makes it worthwhile?
    Blinman, Prunella
    McLachlan, Sue-Anne
    Nowak, Anna
    Duric, Vlatka
    Wright, Gavin
    Millward, Michael
    Brown, Chris
    Coskinas, Xanthi
    Fong, Kwun
    Stockler, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S581 - S581
12345